Alliance Wealth Advisors LLC Sells 50 Shares of Eli Lilly and Company (NYSE:LLY)

Alliance Wealth Advisors LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 738 shares of the company’s stock after selling 50 shares during the period. Alliance Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $570,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Northeast Investment Management boosted its position in Eli Lilly and Company by 4.3% in the fourth quarter. Northeast Investment Management now owns 53,478 shares of the company’s stock valued at $41,285,000 after buying an additional 2,226 shares in the last quarter. Summit Wealth & Retirement Planning Inc. boosted its holdings in shares of Eli Lilly and Company by 84.5% in the 4th quarter. Summit Wealth & Retirement Planning Inc. now owns 546 shares of the company’s stock worth $422,000 after acquiring an additional 250 shares in the last quarter. Investment Advisory Services Inc. TX ADV grew its position in Eli Lilly and Company by 8.1% during the 4th quarter. Investment Advisory Services Inc. TX ADV now owns 322 shares of the company’s stock worth $248,000 after acquiring an additional 24 shares during the last quarter. WCM Investment Management LLC increased its holdings in Eli Lilly and Company by 26.0% during the 4th quarter. WCM Investment Management LLC now owns 16,705 shares of the company’s stock valued at $12,927,000 after purchasing an additional 3,445 shares in the last quarter. Finally, Entropy Technologies LP boosted its stake in Eli Lilly and Company by 113.6% in the fourth quarter. Entropy Technologies LP now owns 8,141 shares of the company’s stock worth $6,285,000 after purchasing an additional 4,329 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Citigroup decreased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Bank of America reissued a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Trading Down 1.1 %

LLY opened at $868.57 on Tuesday. The firm’s fifty day moving average is $789.87 and its two-hundred day moving average is $843.19. The firm has a market cap of $824.55 billion, a PE ratio of 74.17, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Equities research analysts anticipate that Eli Lilly and Company will post 23.33 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s payout ratio is currently 44.41%.

Eli Lilly and Company declared that its Board of Directors has authorized a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.